Pfizer raised its full-year revenue and profit forecasts on Tuesday after third-quarter results beat Wall Street expectations, and it named Cecile Guegan its chief financial officer.

The drugmaker reported revenue of $16.58 billion, compared with analyst estimates of $15.87 billion, and adjusted earnings of 87 cents a share, 14 cents above estimates, Reuters reported, citing LSEG data. CNBC (opens in new tab) said revenue was roughly flat from a year earlier. Net income was $3.24 billion, or 56 cents a share, down from $3.54 billion, or 62 cents, a year ago, CNBC (opens in new tab) reported.

Pfizer now expects 2026 revenue of $62 billion to $64 billion, up from $60.5 billion to $62.5 billion, and adjusted earnings of $2.95 to $3.05 a share, up from $2.80 to $3.00. CNBC (opens in new tab) reported that the earnings outlook includes a $650 million charge, or about 10 cents a share, related to a deal with Innovent.

Sales of the blood thinner Eliquis, which Pfizer shares with Bristol Myers Squibb, rose 25% to $2.52 billion, which the company attributed to a higher net price in the U.S., according to Reuters. Padcev, a cancer drug Pfizer gained through its $43 billion purchase of Seagen, brought in $720 million, CNBC (opens in new tab) reported. Covid vaccine sales were $808 million and Paxlovid sales $449 million.

Guegan, who had been interim finance chief since August, took the job effective Nov. 1. She succeeds Dave Denton, who left to become CFO of Nike. BMO Capital analyst Evan Seigerman told Reuters the appointment provides “more perceived stability ahead of decisions on setting 2027 guidance.”

Chief Executive Albert Bourla said the higher outlook reflected the quarter’s performance and confidence in the company’s strategy and pipeline, Reuters reported. Pfizer also said late-stage data for its experimental cancer drug mevrometostat, previously expected by year-end, is now due in the first quarter of 2027.

Pfizer shares were down nearly 1% at $30.37 in midday trading, according to Reuters.